Home
About Us
Group Introduction
Founder Introduction
Global Cooperation
Nanolattix Biotechnology
Company Profile
Development History
Research Layout
Nanolattix Health
Extraction Platform
Cosmetics
Machine
Food Brand
Disinfection
Oem/Odm
News
Company News
Industry News
Contact Us
简体中文
English
Release time:
2025-01-10
Nanolattix Completes Tens of Millions in Series A Financing
Tag:
Previous Page
2024.4
None
Next Page
Previous Page:
Next page:
recommend News
Nanolattix Chairperson Dr. Zhican Qu Attends BIO 2025, Showcasing China's Biopharma Innovation
2025-07-09
Clinical Trial Recruitment for T320, a Novel TF-Targeting Anti-Cancer Drug
Nanolattix’s T320-ADC Multi-Center Clinical Trials Initiated, Accelerating Development of Advanced Solid Tumor Therapies
Chain-Driven Frontier Nuclear Medicine Innovation | Nanolattix Chairman Qu Zhican Attends BIOCHINA 2026
2026-03-16
Nanolattix's Nuclear Drug RT01 Completes First Dosing in Clinical IIT, Seizing the New High Ground of "RDC + ADC" Theranostics Integration
2026-03-03
Share
